Sanofi had one of only two licensed dengue vaccines, Dengvaxia, and the only vaccine licensed in the United States. The company recently announced it will stop manufacturing Dengvaxia, and ...

While many infections are mild, the disease can progress to severe forms, such as dengue hemorrhagic fever or dengue shock syndrome ... The dengue vaccine, Dengvaxia™, is an option for ...

causing dengue hemorrhagic shock. In this brief article, I will summarize and discuss the diagnosis and treatment of this disease. For diagnosis of dengue, most tropical doctors make use of ...

While the WHO-approved vaccine, Dengvaxia, and antiviral treatments like Balapiravir and Celgosivir are ... DHF, Dengue Hemorrhagic Fever; DSS, Dengue Shock Syndrome; EANPDB, Eastern Africa Natural ...

The World Health Organization, which had been campaigning for vaccines to treat Dengue is reviewing the data. It has now recommended that Dengvaxia should only be given to previously infected ...

Streptococcal toxic shock syndrome from group A streptococcal disease is rare in the postpartum period, yet it is associated with high morbidity and mortality. Early diagnosis and treatment can ...

Dengvaxia showed 60% efficacy. It is now limited to individuals with previous dengue fever, and it is not available in non-endemic countries. In 2023, the Qdenga vaccine for dengue had been approved ...

Dengue fever is unusual in that a first infection is rarely serious, but a second can lead to a much more serious form of the disease. Dengvaxia is only recommended in those who have previously ...